» Articles » PMID: 20635443

Impacts of Cytosolic Phospholipase A2, 15-prostaglandin Dehydrogenase, and Cyclooxygenase-2 Expressions on Tumor Progression in Colorectal Cancer

Overview
Journal Yonsei Med J
Specialty General Medicine
Date 2010 Jul 17
PMID 20635443
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: In addition to cyclooxygenase-2 (COX-2) which is related to prostaglandin E2 synthesis, other enzymes such as cytosolic phospholipase A2 (cPLA2), microsomal prostaglandin E2 synthase-1 (mPGES-1), and 15-prostaglandin dehydrogenase (15-PGDH) have been suggested to be related to carcinogenesis of colorectal cancer (CRC). The aim of this study was to investigate the roles of cPLA2, COX-2, mPGES-1, and 15-PGDH in tumor progression.

Materials And Methods: cPLA2, COX-2, mPGES-1, 15-PGDH, and vascular endothelial growth factor (VEGF) expressions were immunohistochemically examined in 89 CRC, and their expressions were compared with each other or clinicopathologic parameters as well as VEGF as tumor progression parameters.

Results: cPLA2 was expressed in 54.5%, COX-2 in 80.5%, mPGES-1 in 96.4%, 15-PGDH in 46.1%, and VEGF in 65.9%. The expression of cPLA2 correlated with VEGF expression. COX-2 expression was correlated with the depth of invasion, tumor stage, cPLA2, and VEGF expressions. Moreover, VEGF revealed the highest expression in the tissues positive for both cPLA2 and COX-2. Furthermore, 15-PGDH expression was inversely correlated with VEGF expression.

Conclusion: The present study demonstrates that cPLA2 and mPGES-1, in addition to COX-2, are constitutively overexpressed, and that 15-PGDH might be attenuated in colorectal cancer. Furthermore, cPLA2 and 15-PGDH as well as COX-2 could have an important role in tumor progression.

Citing Articles

Non-Targeted Serum Lipidomics Analysis and Potential Biomarkers of Laryngeal Cancer Based on UHPLC-QTOF-MS.

Wang H, Luo Y, Chen H, Hou H, Hu Q, Ji M Metabolites. 2022; 12(11).

PMID: 36355170 PMC: 9695307. DOI: 10.3390/metabo12111087.


Upregulation of prostaglandin E2 by inducible microsomal prostaglandin E synthase-1 in colon cancer.

Kim Y, Kim K Ann Coloproctol. 2021; 38(2):153-159.

PMID: 34465013 PMC: 9021850. DOI: 10.3393/ac.2021.00374.0053.


Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer.

Ismail N, Othman I, Abas F, Lajis N, Naidu R Int J Mol Sci. 2019; 20(10).

PMID: 31108984 PMC: 6566943. DOI: 10.3390/ijms20102454.


CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.

Nasry W, Wang H, Jones K, Dirksen W, Rosol T, Rodriguez-Lecompte J Vet Sci. 2018; 5(3).

PMID: 30104530 PMC: 6163611. DOI: 10.3390/vetsci5030072.


Nanoliposomal delivery of cytosolic phospholipase A inhibitor arachidonyl trimethyl ketone for melanoma treatment.

Gowda R, Dinavahi S, Iyer S, Banerjee S, Neves R, Pameijer C Nanomedicine. 2018; 14(3):863-873.

PMID: 29317343 PMC: 5899023. DOI: 10.1016/j.nano.2017.12.020.


References
1.
Laye J, Gill J . Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov Today. 2003; 8(15):710-6. DOI: 10.1016/s1359-6446(03)02754-5. View

2.
Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S . Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol. 2005; 208(3):356-63. DOI: 10.1002/path.1907. View

3.
Bonventre J, Huang Z, Taheri M, OLeary E, Li E, Moskowitz M . Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997; 390(6660):622-5. DOI: 10.1038/37635. View

4.
Zhang H, Sun X . Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol. 2002; 97(4):1037-41. DOI: 10.1111/j.1572-0241.2002.05625.x. View

5.
Soumaoro L, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K . Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004; 10(24):8465-71. DOI: 10.1158/1078-0432.CCR-04-0653. View